Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Cash from Financing Activities (2023 - 2025)

Immunome (IMNM) has disclosed Cash from Financing Activities for 3 consecutive years, with $432.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities rose 2054.82% year-over-year to $432.8 million, compared with a TTM value of $640.4 million through Dec 2025, up 166.23%, and an annual FY2025 reading of $640.4 million, up 166.23% over the prior year.
  • Cash from Financing Activities was $432.8 million for Q4 2025 at Immunome, up from $45.4 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $432.8 million in Q4 2025 and bottomed at -$55000.0 in Q2 2025.
  • Average Cash from Financing Activities over 3 years is $90.7 million, with a median of $45.4 million recorded in 2025.
  • The sharpest move saw Cash from Financing Activities soared 645326.47% in 2024, then tumbled 107.93% in 2025.
  • Year by year, Cash from Financing Activities stood at $55.5 million in 2023, then plummeted by 63.81% to $20.1 million in 2024, then skyrocketed by 2054.82% to $432.8 million in 2025.
  • Business Quant data shows Cash from Financing Activities for IMNM at $432.8 million in Q4 2025, $45.4 million in Q3 2025, and -$55000.0 in Q2 2025.